# Table of Contents

Preface ................................................................. xiii
About the Editor ...................................................... xv

1. **Donor Apheresis Separators and Their Development.** ................. 1  
   *Daniel D. Summerfield, MD, and Edwin A. Burgstaler, MT, HP(ASCP)*  
   Early History .................................................. 2  
   Principles of Operation ....................................... 4  
   Approaches Over Time. ....................................... 5  
   Current Instrumentation ..................................... 8  
   Comparison of Current Apheresis Systems ................. 26  
   Summary ....................................................... 32  
   Suggested Readings .......................................... 32

2. **Physiology of Donor Apheresis and Donor Reactions.** ................. 33  
   *P. Dayand Borge, MD, PhD, and Leonard N. Chen, MD, PhD*  
   Anticoagulation ................................................ 34  
   Fluid Shifts .................................................. 42  
   Platelet Loss and Lymphocyte Depletion ....................... 43  
   Adverse Effects ............................................... 45  
   Suggested Readings .......................................... 48

3. **Selection and Care of the Apheresis Donor.** ........................... 51  
   *Eileen Galvin Karr, RN, BSN, HP(ASCP)QIA, and*  
   *Antonia Hagen-Coonradt, RN,BSB*  
   Donor Recruitment, Education, and Conversion ............... 52  
   Staff Training ............................................... 54  
   Donation Eligibility ......................................... 54  
   TRALI Mitigation ............................................. 56  
   Emerging Infectious Diseases ................................ 56  
   Donor Comfort and Venipuncture ............................. 57  
   Apheresis Equipment and Donor Care ......................... 59  
   Granulocyte Donors .......................................... 59  
   Suggested Readings .......................................... 61
Table of Contents

8. Bacterial Contamination of Platelet Products ....................... 127
   Stephen J. Wagner, PhD
   Clinical Presentation of Septic Transfusion Reactions .............. 129
   Organisms and Sources ............................................. 130
   Methods to Reduce the Risk of Transfusion-Associated Sepsis ....... 131
   Conclusion ........................................................... 138
   Suggested Readings .................................................. 138

9. Pathogen Inactivation Technologies for Blood Components .......... 141
   Cyril Jacquot, MD, PhD; Burak Bahar, MD; and Meghan Delaney, DO, MPH
   Decreasing the Risk of Transfusion-Associated Sepsis ............... 142
   Overview of Pathogen Inactivation ................................ 143
   Pathogen Reduction/Inactivation Methodologies ....................... 143
   Efficacy against Pathogens and Limitations ........................ 148
   Clinical Effectiveness of Platelets after PI Treatment ............. 149
   Special Considerations for Pediatric Use .......................... 149
   Effect of PRT on Collection, Storage, Quality, and Cost ........... 150
   Ongoing Monitoring of PI for Effectiveness and Adverse Events ... 153
   Plasma PI and Its Effects ........................................... 153
   Future Directions ..................................................... 154
   Suggested Readings ................................................... 154

10. HLA-Compatible Platelets ........................................... 157
    Roger Belizaire, MD, PhD, and Robert S. Makar, MD, PhD
    HLA Alloimmunization and Platelet Transfusions .................... 158
    ABH and Platelet-Specific Antigens and Platelet Transfusion ...... 160
    Diagnosis of Alloimmune Refractoriness .......................... 164
    Matched Platelets in the Management of the Alloimmunized Patient 166
    Other Approaches to the Management of Thrombocytopenia and Persistent Platelet Transfusion Refractoriness ...................... 171
    The HLA-Typed Donor Pool in a Matched Donor Program ............. 171
    Suggested Readings .................................................. 172

11. Granulocyte (Neutrophil) Transfusion ............................. 175
    Corinne Goldberg, MD, and Jeffrey McCullough MD
    Neutrophil (PMN) Physiology ....................................... 176
    Clinical Indications for Granulocyte Transfusions ................ 177
    Clinical Experience with Granulocyte Transfusions ................ 177
    Clinical Efficacy ..................................................... 177
    Experience with Neonates and Pediatric Patients .................. 181
    Transfusion Guidelines .............................................. 182
    Granulocyte Transfusion-Associated Adverse Reactions ............. 182
    Technical Considerations: Donor Granulocyte Collection and Manufacture 183
12. Quality Management in Apheresis. ................................. 189

Eric Senaldi, MD

Background ................................................................. 190
Employee Categories and Roles ........................................ 192
Employee Preparation .................................................... 195
Management of the Apheresis Unit—Operations .................. 196
Management of the Apheresis Unit—Quality Systems .......... 198
Minimum Quality System Elements ................................. 199
Suggested Readings ...................................................... 210

Index ............................................................................ 213